Overview
Sponsored by the American College of Chest Physicians.
Supported by an educational grant from Gilead Sciences Medical Affairs.
Program Description
In the last several years, new therapeutic options for pulmonary hypertension have emerged. Nevertheless, clinicians treating patients with pulmonary hypertension are faced with important questions that this session will address. How should we use current guidelines when initiating therapy? What are the options and when should we escalate treatment? What are the differences between various therapeutic agents? This important debate draws on experience from experts in pulmonary hypertension to relate the subtleties of treating this devastating disease. This session highlights the complexities of the disease and the therapeutic challenges faced, especially with the multitude of agents available.
In this web-based format, participants have the opportunity to obtain the information as it was originally presented by watching the video slide presentations on line, downloading the slides for review, or downloading a written executive summary of the presentations to read. Following their review of the presentations, participants will be asked relevant test questions as part of the evaluation process to obtain CME credit.
Educational Objectives
- Describe the current guidelines for therapies for pulmonary hypertension.
- Recognize patients with severe disease and determine the best treatment options.
- Identify differences among and within therapeutic classes available for treatment of pulmonary hypertension.
Target Audience
Advanced practice nurses, cardiologists, critical care physicians, fellows-in-training, general medicine physicians, physician assistants, pulmonary physicians, registered nurses, respiratory therapists
Needs Assessment
Clinicians treating patients with pulmonary hypertension are faced with important questions that this session tries to answer: How should we use current guidelines when initiating therapy? What are the options and when to escalate treatment? What are the differences between various therapeutic agents? This important debate brings to the table experience from experts in pulmonary hypertension and relates the subtleties of the treatment of this devastating disease. It highlights the complexities of the disease and also the therapeutic challenges, even with the multitude of agents available.
Faculty
Lewis J. Rubin, MD, FCCP
Professor of Medicine
Director, Pulmonary Hypertension Program
University of California
San Diego Medical Center
La Jolla, CA
David B. Badesch, MD, FCCP
Professor of Medicine
Clinical Director, Pulmonary Hypertension Center
University of Colorado Health Sciences Center
Denver, CO
Nazzareno Galiè, MD
Associate Professor of Cardiology
Director, Pulmonary Hypertension Center
Institute of Cardiology, University of Bologna
Bologna, Italy
Vallerie V. McLaughlin, MD, FCCP
Associate Professor of Medicine
Director, Pulmonary Hypertension Program
University of Michigan
CVC Cardiovascular Medicine
Ann Arbor, MI
CME & Disclaimers
Release: March 2009
CME Expiration: December 31, 2009
Estimated completion time: 2 hours
This CME product is a Web-based activity. Participants will watch and listen to a Webcast slide presentation, and complete an activity evaluation to obtain CME.
Accreditation - Designation
The American College of Chest Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American College of Chest Physicians designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Anyone who attended the Evidence-Based Treatment of Pulmonary Arterial Hypertension in an Evolving Environment session at CHEST 2008 when this content was presented and already claimed CME for this presentation cannot claim CME from this enduring product.
Disclosure Statement
The ACCP remains strongly committed to providing the best available evidence-based clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of the ACCP to eliminate all situations of potential conflict of interest, but rather to enable those who are working with the ACCP to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the educational activity course director/chair, the Education Committee, or the Conflict of Interest Review Committee to ensure that such situations are properly evaluated and, if necessary, resolved. The ACCP educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all ACCP CME activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available on-site during all educational activities.
The following faculty members of this educational activity have disclosed to the ACCP that a relationship does exist with the respective company/organization as it relates to their presentation of material and should be communicated to the participants of this educational activity:
Lewis J. Rubin, MD, FCCP
Grant monies (from sources other than industry): NIH
Grant monies (from industry-related sources): NHBLI, Actelion, Pfizer, United Therapeutics, MondoBiotech, MD Primer, Gilead
Shareholder: LungRx
Employee: University of California at San Diego, School of Medicine
Consultant fee, speaker bureau, advisory committee, etc: NHBLI, Actelion, Pfizer, United Therapeutics, Aires Pharmaceuticals, Bayer Schering Pharma, AG MondoBiotech, Novartis, Jerini AG, EPIX Pharmaceuticals Broncus Technologies, Solvay Pharmaceuticals, Cogentus Pharmaceuticals, GeneraMedix Pharmaceuticals Inc.
Other: Gerson Lehrman Group, MEDACorp Clinical Advisors, Piper Jaffray & Co, Citigroup Investment Research, Vista Research, Concert Pharmaceuticals, Inc.,
Product/procedure/technique that is considered research and is NOT yet approved for any purpose: Nitric oxide
David B. Badesch, MD, FCCP
Grant monies (from sources other than industry): NIH
Grant monies (from industry-related sources): Actelion/CoTherix, United Therapeutics/Lung Rx, ICOS/Lilly, Pfizer, Gilead/Myogen, Encysive
Fiduciary position (of any organization, association, society, etc, other than ACCP: Pulmonary Hypertension Association Board of Directors
Consultant fee, speaker bureau, advisory committee, etc: GlaxoSmithKline, Actelion/CoTherix, Gilead/Myogen, Encysive, MondoBIOTECH, MondoGen, Biogen IDEC, Pfizer, United Therapeutics/ Lung Rx
Product/procedure/technique that is considered research and is NOT yet approved for any purpose: Sitaxsentan
Vallerie V. McLaughlin, MD, FCCP
Grant monies (from industry-related sources): Actelion, Pfizer, United Therapeutics
Consultant fee, speaker bureau, advisory committee, etc: Actelion, Gilead, Pfizer
Nazzareno Galiè, MD
Grant monies (from industry-related sources): Institute received grant support from Pfizer, Actelion, Schering, Encysive, United Therapeutics, Eli-Lilly, and Myogen
Consultant fee, speaker bureau, advisory committee, etc: Pfizer, Actelion, Schering, Encysive, Myogen, GSK, Ely-Lilly, and MondoBIOTECH
Disclaimer
The American College of Chest Physicians (“ACCP”) and its officers, regents, executive committee members, members, related entities, employees, representatives and other agents (collectively, “ACCP Parties”) are not responsible in any capacity for, do not warrant and expressly disclaim all liability for, any content whatsoever in any ACCP publication or other product (in any medium) and the use or reliance on any such content, all such responsibility being solely that of the authors or the advertisers, as the case may be. By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any ACCP publication or other product. Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the ACCP Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.
CME Instructions
CME for this activity is available through December 31, 2009. To receive CME credit and print your certificate, complete an online evaluation:
- Go to www.chestnet.org, and click on the “CME Certificates” icon.
- Log in using your ACCP ID number or e-mail address on file with the ACCP. Enter your ACCP ID number, and click submit, OR, if you do not have an ACCP ID number, click on the link “Create an account here.”
- To locate the product for which you want to claim CME credit, look under the “Available CME” tab on the left navigation bar.
- Click the “Claim Credit” link next to the product to begin the certificate process.
- Complete any required posttest and evaluation. Please be sure to check the box that states you are finished with the evaluation.
- Once you submit the evaluation, your CME certificate will be created and will show under the tab, “My CME History.” You can print it at any time by clicking the “Certificate” link.
If you need help, please contact the CME Administrator via e-mail at CME@chestnet.org, or leave a voice mail message at (847) 498-8376. For faster assistance, please outline the specific problem you are having, and provide your ACCP ID and contact information.
Related Materials
Download a Written Summary (pdf)
Download the Presentation Slides (pdf)
First-line Therapy: How To Choose
David B. Badesch, MD, FCCP
Combination Therapy: Why, When, and Which
Lewis J. Rubin, MD, FCCP
How and What To Monitor When Following Patients With PAH
Vallerie V. McLaughlin, MD, FCCP
Future Directions: Highlighting Novel Drug Candidates and Alternative Approaches to Therapy
Nazzareno Galiè, MD
Search Archives
Search the ACCP archives for CME and non-CME related material. To see our entire archive put a * in the field below and hit search.
Submit Feedback
The ACCP is interested in your feedback concerning A Physician's Perspective®.
